GO
Loading...

Pharmaceuticals

More

  • The medical research companies Quest Diagnostics and Quintiles will form a joint venture to conduct clinical trial laboratory work for drug developers. Quest Diagnostics Inc., based in Madison, New Jersey, provides diagnostic testing and other services through a network of laboratories and patient service centers. Shares of Quest Diagnostics slipped 9...

  • Actavis selling Australian generic drug unit to Amneal Tuesday, 31 Mar 2015 | 7:37 AM ET

    NEW YORK— Actavis PLC is selling its generic drug business in Australia to privately-held Amneal Pharmaceuticals for an undisclosed amount. Ireland- based Actavis said it will continue to supply the Australian market with generic medicines and fulfill supply commitments for all hospital tenders until the deal is complete. Earlier this month, Actavis...

  • The policy adopted by American Pharmacists Association delegates at their annual meeting Monday makes an ethical stand against providing such drugs, saying they run contrary to the role of pharmacists as health care providers. "Now there is unanimity among all health professions in the United States who represent anybody who might be asked to be involved in...

  • US pharmacist group moves to block execution drugs Monday, 30 Mar 2015 | 6:44 PM ET
    Hypodermic needle filled from vial

    A national pharmacists' group has adopted a policy discouraging its members from providing death-penalty drugs.

  • The declaration approved by American Pharmacists Association delegates at their annual meeting held in San Diego this year says the practice of providing lethal-injection drugs is contrary to the role of pharmacists as health care providers. "Now there is unanimity among all health professions in the United States who represent anybody who might be asked...

  • *China shares hit seven-year high on ambitious Silk Road project. Also Monday, Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for $3.5 billion, and Ireland's Horizon Pharma Plc agreed to buy U.S. drugmaker Hyperion Therapeutics Inc for about $1.1 billion. Earlier, China unveiled details of an...

  • NEW YORK, March 30- UnitedHealth Group Inc's planned takeover of No. 4 U.S. pharmacy benefits provider Catamaran Corp will give the companies added heft in price talks with drug companies, serving as a catalyst for deals allowing other insurers to bulk up. The $12.8 billion deal comes at a time when Wall Street has been parsing the possibilities that top insurers...

  • UnitedHealth's $12.8B deal   Monday, 30 Mar 2015 | 2:03 PM ET
    UnitedHealth's $12.8B deal

    CNBC's Meg Tirrell reports on health care consolidation and PBM stocks to watch.

  • Catamaran leads Nasdaq   Monday, 30 Mar 2015 | 1:00 PM ET
    Catamaran leads Nasdaq

    CNBC's Bertha Coombs reports on healthcare stock deals including Catamaran to be acquired by UnitedHealth for $12.8B.

  • *Novartis commits $225 mln upfront to private biotech firm. *Novartis also picks top scientist to lead immuno-oncology. March 30- Swiss drugmaker Novartis is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech worth up to $750 million.

  • *NY AG test also confirms GNC's products meet FDA guidelines. *Probe into Walgreens, Wal-Mart, Target products ongoing. GNC also agreed to adopt testing standards for herbal supplements that exceed FDA requirements, a first in the United States, Attorney General Eric Schneiderman said in a statement.

  • *China shares hit seven-year high on new Silk Road project. NEW YORK, March 30- The dollar rose and global equity markets surged on Monday on merger and acquisition activity among drugmakers on both sides of the Atlantic, while Chinese stocks hit a seven-year high on an ambitious government plan to create a modern Silk Road. Earlier, China unveiled details of an...

  • Faber Report: Health care deals   Monday, 30 Mar 2015 | 10:06 AM ET
    Faber Report: Health care deals

    CNBC's David Faber discusses three multi-billion dollar pharma deals helping to push the market higher including Teva buying Auspex.

  • March 30- GNC Holdings Inc said it restored certain dietary supplements to its stores in New York after reaching an agreement with the state's attorney general that its products complied with the Food and Drug Administration's guidelines. GNC also agreed to adopt stricter testing standards for herbal supplements that exceed FDA requirements, a first in the...

  • Encouraging U.S. economic data and a batch of corporate deals put investors in a buying mood Monday, sending stocks sharply higher. The broad rally nudged the Dow Jones industrial average back into positive territory for the year after a rough stretch for the market most of last week. "You had all the elements today for a positive market," said Quincy Krosby, market...

  • March 30- Ireland's Horizon Pharma Plc struck a deal to buy U.S. drugmaker Hyperion Therapeutics Inc for about $1.1 billion to add to its line-up of drugs that treat rare diseases. Hyperion's shares were trading at $45.90 before the bell, while Horizon's were at $25.70. Ravicti and Buphenyl are expected to add $100 million to adjusted EBITDA in 2016 and result in...

  • March 30- Nutritional supplements maker GNC Holdings Inc said it had reached an agreement with the New York Attorney General, affirming its Herbal Plus products were in compliance with the Food and Drug Administration's guidelines. The company was one of four in February to remove these dietary supplements from their shelves in New York after they got...

  • Perrigo expands with Omega   Monday, 30 Mar 2015 | 7:47 AM ET
    Perrigo expands with Omega

    Perrigo is set to close a huge deal for Omega Pharmaceuticals. Perrigo CEO Joseph Papa, discusses the benefits of the deal, and the company's move to Ireland.

  • Teva buying Auspex for $3.2 billion Monday, 30 Mar 2015 | 7:31 AM ET

    NEW YORK— Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments. Jerusalem- based Teva said Monday that it will pay $101 per share, marking a 47 percent premium to San Diego- based Auspex's closing stock price on Friday.

  • Teva to buy Auspex for $101/share in cash Monday, 30 Mar 2015 | 7:09 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.